Cargando…

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

BACKGROUND: Targeted therapies have improved survival and quality of life for patients with non-small-cell lung cancer with actionable driver mutations. However, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 gene (HER2, also known as ERBB2) exon 20 insertions (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirchner, M., Kluck, K., Brandt, R., Volckmar, A.-L., Penzel, R., Kazdal, D., Endris, V., Neumann, O., Seker-Cin, H., Goldschmid, H., Glade, J., Allgäuer, M., Kriegsmann, M., Winter, H., Muley, T., Perner, S., Frost, N., Reck, M., Fröhling, S., Schirmacher, P., Thomas, M., Budczies, J., Christopoulos, P., Stenzinger, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426209/ https://www.ncbi.nlm.nih.gov/pubmed/34487971 http://dx.doi.org/10.1016/j.esmoop.2021.100253

Ejemplares similares

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
por: Rempel, E., et al.
Publicado: (2022)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie
por: Kahles, Andy, et al.
Publicado: (2023)

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
por: Kirchner, Martina, et al.
Publicado: (2019)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
por: Budczies, Jan, et al.
Publicado: (2022)

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
por: Kazdal, Daniel, et al.
Publicado: (2021)

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer
por: Kazdal, Daniel, et al.
Publicado: (2017)

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
por: Romanovsky, Eva, et al.
Publicado: (2023)

Struktur und Inhalt der EU-IVDR: Bestandsaufnahme und Implikationen für die Pathologie
por: Kahles, Andy, et al.
Publicado: (2022)

Structure and content of the EU-IVDR: Current status and implications for pathology
por: Kahles, Andy, et al.
Publicado: (2023)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
por: Volckmar, Anna-Lena, et al.
Publicado: (2016)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib
por: Kunz, Julia, et al.
Publicado: (2022)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients
por: Menzel, Michael, et al.
Publicado: (2023)

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Genetic changes of non-small cell lung cancer under neoadjuvant therapy
por: Warth, Arne, et al.
Publicado: (2016)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer
por: Kriegsmann, Mark, et al.
Publicado: (2018)

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples
por: Kriegsmann, Katharina, et al.
Publicado: (2021)

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
por: El Shafie, R.A., et al.
Publicado: (2021)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ggkt67indqkcma290asfsukn8i